Sophia Genetics SA美股招股说明书(2026-06-16版)

Ordinary Shares We are sellingordinary shares, with a nominal value CHF 0.05 per share, in this offering. We have granted the underwriters an option to purchase up to an additionalordinary shares, at the publicoffering price, less the underwriting discounts and commissions, for 30 days after the date of this prospectussupplement. Our ordinary shares are listed on the Nasdaq Global Select Market under the symbol “SOPH.” On June15, 2026,the last reported sale price of our ordinary shares on the Nasdaq Global Select Market was $5.01 per share. We are an “emerging growth company” as defined under U.S. federal securities laws and, as such, elect to complywith reduced public company reporting requirements. See “Prospectus Supplement Summary—Implications of Beingan Emerging Growth Company and Foreign Private Issuer.” Investing in our ordinary shares involves a high degree of risk. Before making an investment decision, youshould carefully review the risks and uncertainties described under the heading “RiskFactors” beginningon page S-7 of this prospectus supplement and in the other documents that are incorporated by referenceherein. You should read the entire prospectus supplement and the accompanying prospectus, including anyinformation incorporated by reference herein or therein, carefully before you make your investmentdecision. Neither the Securities and Exchange Commission nor any state securities commission has approved ordisapproved of these securities or determined if this prospectus supplement or the accompanyingprospectus is truthful or complete. Any representation to the contrary is a criminal offense. Public offering price Underwriting discounts and commissions(1)Proceeds, before expenses, to us (1)We refer you to “Underwriting” beginning on page S-22 for compensation payable to the underwriters. The underwriters expect to deliver the ordinary shares to the purchasers on or about, 2026 through thebook entry facilities of The Depository Trust Company. Lead Book-running ManagerTD Cowen June,2026. Table of Contents TABLE OF CONTENTS Prospectus Supplement About This Prospectus SupplementProspectus Supplement SummaryRisk FactorsCautionary Statement Regarding Forward-Looking StatementsUse of ProceedsCapitalizationDilutionTaxationUnderwritingLegal MattersExpertsWhere You Can Find More InformationInformation Incorporated by Reference Prospectus About This ProspectusOur CompanyRisk FactorsCautionary Statement Regarding Forward-Looking StatementsUse of ProceedsDividend PolicyDescription of Share Capital and Articles of Association Description of Debt Securities Description of Warrants Description of Subscription Rights Legal Matters Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering.The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf”registration process. The accompanying prospectus provides you with a general description of the securities that may be offered by us,some of which may not apply to this offering. This prospectus supplement and the information incorporated by reference in this prospectussupplement adds to, updates and, where applicable, modifies and supersedes information contained or incorporated by reference in theaccompanying prospectus. Before buying any of the securities that we are offering, you should carefully read both this prospectus supplement and theaccompanying prospectus with all of the information incorporated by reference in this prospectus supplement, as well as the additionalinformation described under the heading “Where You Can Find More Information” and “Information Incorporated by Reference.” Thesedocuments contain important information that you should consider when making your investment decision. We have filed or incorporatedby reference exhibits to the registration statement of which the accompanying prospectus forms a part. You should read the exhibitscarefully for provisions that may be important to you. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and theinformation contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, onthe other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documentsis inconsistent with a statement in another document having a later date—for example, a document incorporated by reference in thisprospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. The information contained in this prospectus supplement, the accompanying prospectus or any document incorporated by referencein this prospectus supplement is accurate only as of their respective dates, rega